- Home
- GLRE vs SPRY Comparison
GLRE vs SPRY Comparison
Compare GLRE & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | SPRY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 415.7M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLRE | SPRY |
|---|---|---|
| Price | $15.31 | $4.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 101.3K | ★ 1.4M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $52.57 |
| Revenue Next Year | N/A | $45.52 |
| P/E Ratio | $83.03 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $3.81 |
| 52 Week High | $19.39 | $13.15 |
Technical Indicators
Market Signals| Indicator | GLRE | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 46.54 |
| Support Level | $14.53 | $4.00 |
| Resistance Level | $15.48 | $4.60 |
| Average True Range (ATR) | 0.38 | 0.26 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 89.27 | 55.15 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.